2023 World Conference on Lung Cancer (Posters)-EP08.02. FDG PET Scan Based Response Assesment in Non-Small Cell Lung Cancer Treated With Chemoradiotherapy And Neoadjuvant Chemotherapy

EP08.02. FDG PET Scan Based Response Assesment in Non-Small Cell Lung Cancer Treated With Chemoradiotherapy And Neoadjuvant Chemotherapy - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the use of FDG PET scans for assessing treatment response in patients with non-small cell lung cancer (NSCLC) who received chemoradiotherapy (CRT) or neoadjuvant chemotherapy (NACT). The study included 27 patients with stage III NSCLC, with 22 adenocarcinoma and 5 squamous cell carcinoma. The patients were divided into different treatment groups, including those who received NACT followed by concurrent chemoradiotherapy (CCRT), those who received only NACT, and those who received only CCRT. <br /><br />FDG PET scans were performed before and after treatment, and the tumor size and maximum standardized uptake value (SUVmax) were measured. The study found that NACT followed by CCRT in adenocarcinoma patients resulted in better control of tumor size and metabolic activity on FDG PET scans. Patients with squamous cell carcinoma who received only NACT also responded well to treatment. There was no association between smoking history and treatment response on PET scans. <br /><br />The study concluded that NACT followed by CCRT can be an effective treatment approach for adenocarcinoma patients with NSCLC. However, further prospective trials are needed to validate these findings and explore new radiotherapy techniques and neoadjuvant chemoradiotherapy in NSCLC. Overall, this study highlights the importance of FDG PET scans in assessing treatment response and guiding treatment decisions for patients with NSCLC.

Asset Subtitle

Aftab Ahmad

Meta Tag

Speaker Aftab Ahmad

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

FDG PET scans

treatment response

NSCLC

chemoradiotherapy

adenocarcinoma

squamous cell carcinoma

tumor size

SUVmax

NACT

CCRT